Celgene (NASDAQ: CELG)‘s stock had its “outperform” rating reaffirmed by research analysts at BMO Capital Markets in a report released on Monday. They currently have a $113.00 target price on the stock.
Shares of Celgene traded down 0.66% during mid-day trading on Monday, hitting $104.92. Celgene has a one year low of $58.53 and a one year high of $105.82. The stock’s 50-day moving average is currently $99.50. The company has a market cap of $43.935 billion and a P/E ratio of 32.01.
Celgene last posted its quarterly earnings results on Thursday, January 24th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.01. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter last year, the company posted $1.05 earnings per share. Celgene’s revenue was up 14.0% compared to the same quarter last year. Celgene has set its FY13 guidance at $5.50-5.60 EPS. On average, analysts predict that Celgene will post $5.68 earnings per share for the current fiscal year.
A number of other firms have also recently commented on CELG. Analysts at Cantor Fitzgerald raised their price target on shares of Celgene from $115.00 to $121.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note to investors on Thursday. They now have a $106.00 price target on the stock. Finally, analysts at RBC Capital reiterated an “outperform” rating on shares of Celgene in a research note to investors on Thursday. They now have a $115.00 price target on the stock.
Twenty-two investment analysts have rated the stock with a buy rating, three have issued an overweight rating, and seven have given a hold rating to the company’s stock. The stock presently has a consensus rating of “overweight” and a consensus price target of $111.26.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.